Notoginsenoside R1 alleviates spinal cord injury by inhibiting oxidative stress, neuronal apoptosis, and inflammation via activating the nuclear factor erythroid 2 related factor 2/heme oxygenase-1 signaling pathway

Neuroreport. 2022 Aug 3;33(11):451-462. doi: 10.1097/WNR.0000000000001803. Epub 2022 Jun 27.

Abstract

The secondary injury plays a vital role in the development of spinal cord injury (SCI), which is characterized by the occurrence of oxidative stress, neuronal apoptosis, and inflammatory response. Notoginsenoside R1 (NGR1) has been involved in the modulation of antioxidative stress and anti-inflammatory response. However, its roles in SCI-induced injury are still unknown. We explored the therapeutic effect of NGR1 and its underlying mechanism after SCI by using behavioral, biochemical, and immunohistochemical techniques. The administration of NGR1 after SCI enhanced the neurological function, and mitigated tissue damage and motor neuron loss than those in SCI + vehicle group. Meanwhile, significantly increased expression of Nrf2 protein and HO-1 protein was found in the SCI + NGR1 group compared with those in the SCI + vehicle group. In addition, the inhibitory effects of oxidative stress, apoptotic neuron ratio, and neuronal inflammation in the SCI + NGR1 group can be partially reversed when the Nrf2/HO-1 signaling pathway was inhibited by ML385. Our results indicate that the administration of NGR1 can attenuate oxidative stress, neuronal apoptosis, and inflammation by activating the Nrf2/HO-1 signaling pathway after SCI, thereby improving neurological function.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Apoptosis / drug effects
  • Ginsenosides* / pharmacology
  • Heme Oxygenase-1* / metabolism
  • Humans
  • Inflammation / drug therapy
  • Motor Neurons / drug effects
  • Motor Neurons / metabolism
  • NF-E2-Related Factor 2 / metabolism
  • Oxidative Stress / drug effects
  • Signal Transduction / drug effects
  • Spinal Cord / metabolism
  • Spinal Cord Injuries* / drug therapy
  • Spinal Cord Injuries* / metabolism

Substances

  • Ginsenosides
  • NF-E2-Related Factor 2
  • HMOX1 protein, human
  • Heme Oxygenase-1
  • notoginsenoside R1